KNW - התחייבויות לטווח ארוך להון Know Labs, Inc.

The asset's market dynamics on the GURU.Markets platform serve as an indicator for Know Labs, Inc. (KNW), which is developing non-invasive blood glucose monitoring methods for individuals with metabolic disorders. The project's success depends on FDA certification and testing accuracy maintained at moderate R&D costs, as evidenced by the 0.00 metric. The business's profitability will be based on the implementation of radio-frequency sensors for glucose monitoring.

Assessing the liability structure is critical for filtering the issuer's credit risks. This metric is calculated as the ratio of long-term loans (over one year) to the company's equity. By analyzing the trend of the long-term financial leverage ratio, an investor determines the balance between borrowed capital and asset stability. For Know Labs, Inc. (KNW), the absence of a commercial base makes such borrowings dangerous. High debt dependence while awaiting FDA approval increases financial vulnerability.